Has John Cates received payments from drug or device companies?

Yes. Drug and device makers reported $2,271 in general payments to John Cates across 87 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Cates did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Cates come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Cates

Family Medicine · Anchorage, AKNPI 1558333146

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 87 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $739 and has fallen 75.1% since, to $184 in 2023. Among family medicine clinicians in AK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,271in general payments, 2019–2025

Across 87 payments — averaging $26.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$507
GSK$213
Novo Nordisk$209
AbbVie$203
Novartis$182
Amarin Pharma, Inc.$157
plus $801 from 12 others

What the payments were for

Food & beverage$2,271100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	11	$507
GSK	8	$213
Novo Nordisk	6	$209
AbbVie(2 entities)	12	$203
Novartis	10	$182
Amarin Pharma, Inc.	6	$157
Lilly USA, LLC	4	$137
Merck	8	$128
Bayer	1	$109
Boehringer Ingelheim	2	$108
Pfizer	5	$80
Eisai Inc.	4	$61
Teva Pharmaceuticals USA, Inc.	2	$54
Sanofi-aventis U.S. LLC	4	$53
Biohaven Pharmaceutical Holding Company Ltd.	1	$23
Amgen	1	$19
Nestle Healthcare Nutrition Inc.	1	$17
Biohaven Pharmaceuticals, Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,271 in reported general payments places this provider in the 90th percentile of 334 family medicine providers in Alaska.

See all family medicine providers in Alaska →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	19	$25,320
Repatha SureclickEvolocumab	17	$14,341
Metoprolol Succinate	25	$457
Tamsulosin Hcl	11	$166
Lisinopril	13	$123
Simvastatin	12	$121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Novo NordiskOzempic	$209	$25,32019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 334 family medicine providers in Alaska.

Other family medicine in Anchorage

Mary FolandAnchorage$15K
Ilona FarrAnchorage$14K
Eric MiknichAnchorage$13K
Allison KelliherAnchorage$6K
Bruce KiesslingAnchorage$5K
Kathryn RyanAnchorage$5K
Bruck CliftAnchorage$5K
Ulyana StiassnyAnchorage$4K
Pebbles ShanleyAnchorage$4K
Kenneth MollAnchorage$3K

See the full list for Alaska →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →